Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Geoffrey R. Connors MD, FACP Associate Editor

Virginia A. Brady MD Associate Editor

See All Experts

story of the week

Published in Respiratory Medicine

Journal Scan / Research · August 18, 2022

Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection

Chest

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Emmett Kistler MD

Chest

A Double-blind Randomized Placebo-controlled Phase-3 Trial of Tobramycin Inhalation Solution in Adults with Bronchiectasis with Pseudomonas aeruginosa Infection

Chest 2022 Jul 18;[EPub Ahead of Print], WJ Guan, JF Xu, H Luo, XX Xu, YL Song, WL Ma, ZA Liang, XD Liu, GJ Zhang, XJ Zhang, RK Li, SY Zhu, YJ Zhang, XJ Cai, LP Wei, DB Tian, H Zhao, PY Chen, JM Qu, NS Zhong

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection

Additional Info

A Double-blind Randomized Placebo-controlled Phase-3 Trial of Tobramycin Inhalation Solution in Adults with Bronchiectasis with Pseudomonas aeruginosa Infection

Further Reading

Final Note From the Respiratory Medicine Editors

Prognostic Significance of Right Atrial Volume and Interval Changes in Patients With Idiopathic Pulmonary Arterial Hypertension

Economic Value of Improving Sensitivity Bronchoscopy for Malignancy Diagnosis in Peripheral Pulmonary Lesions

Biomarker-Guided Antibiotic Duration in Patients Hospitalized With Suspected Sepsis

High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure

Global, Regional, and National Mortality Burden Attributable to Air Pollution From Landscape Fires

Benralizumab in the Treatment of Patients With Eosinophilic Exacerbations of Asthma and COPD

Efficacy and Safety of Adjunctive Midodrine Therapy for Vasopressor-Dependent Shock in the ICU

Prevalence of Chronic Airflow Limitation, Emphysema, and Impaired Diffusing Capacity in Relation to Smoking Habits in Middle-Aged Populations

Feasibility of Antibiotic Allergy De-Labeling in the ICU

Impact of Dyspnea on Quality of Life in Adults With Respiratory Symptoms Without a Defined Diagnosis

Recently Updated